Region · 80 analyses
The Gulf has no unified HTA authority and no QALY threshold. Access runs through registration, then a coverage recommendation, then tender — and the sequence is the strategy.
A medicine reaches Gulf patients through a chain, not a decision. It must first be registered with the national regulator, then secure a coverage recommendation, then be included in a ministry tender, state by state. Each link takes time that a launch plan built on a Western HTA calendar will not have allowed for, and the registration queue alone can run one to two years before any coverage body begins its assessment.
Saudi Arabia leads and the region follows, typically with a lag of six to eighteen months, which makes the Saudi coverage position the de facto regional bar. Pricing is set by reference to other countries rather than by cost-effectiveness modelling, then discounted again in negotiation, so Gulf tender prices sit well below US list. Private insurance runs alongside the public route and is frequently faster, which makes it the realistic first channel for a specialty product.
The binding constraint across the region's rare-disease categories is usually diagnosis rather than drug access. Where confirmatory testing sits in a handful of centres, expanding diagnostic capacity does more for uptake than any access argument.
AXLRx GCC reports map that chain for a specific asset: the registration pathway and its realistic timeline, the coverage criteria that will be applied, the tender dynamics that set price, and where the diagnostic bottleneck actually is.